PARLIAMENTARY WRITTEN QUESTION
Blood Cancer (6 March 2017)

To ask the Secretary of State for Health, what discussions he has had with the National Institute for Health and Care Excellence on ensuring that alpha pegylated interferon is made available to patients with myeloproliferative neoplasms.

Asked by:
Rachael Maskell (Labour)

The Department has held no such discussions.

The National Institute for Health and Care Excellence (NICE) has not been asked to develop guidance for the National Health Service on the use of alpha pegylated interferon for the treatment of myeloproliferative neoplasms.

In the absence of guidance from NICE, it is for National Health Service commissioners to make funding decisions on individual treatments based on an assessment of the available evidence.

Answered by:
Baroness Blackwood of North Oxford (Conservative)
14 March 2017